First published 9/28/2026, 9:14:15 AM · Last updated 9/28/2026, 9:14:15 AM

An open‐label, long‐term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder

A 2026 journal article reports results from a long-term, open-label multicenter clinical study assessing venlafaxine extended-release for generalized anxiety disorder in outpatient populations in Japan. The supplied excerpt includes only publisher and content-type metadata and contains no additional study details.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 4/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study assesses the safety and efficacy of a psychiatric medication for a defined patient population in Japan.

Location

Sources

An open‐label, long‐term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder

Report an issue